Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 15 | 2023 | 2027 | 2.300 |
Why?
|
| Liver Neoplasms | 15 | 2023 | 4557 | 1.680 |
Why?
|
| Liver Transplantation | 7 | 2023 | 1112 | 1.460 |
Why?
|
| Hepatitis C, Chronic | 5 | 2023 | 451 | 1.130 |
Why?
|
| Bile Duct Neoplasms | 3 | 2023 | 493 | 0.940 |
Why?
|
| Famotidine | 1 | 2022 | 15 | 0.900 |
Why?
|
| End Stage Liver Disease | 2 | 2023 | 170 | 0.850 |
Why?
|
| Hepatitis C | 3 | 2022 | 524 | 0.850 |
Why?
|
| Sarcopenia | 1 | 2023 | 110 | 0.850 |
Why?
|
| Frailty | 1 | 2023 | 113 | 0.810 |
Why?
|
| Liver Diseases | 2 | 2023 | 574 | 0.790 |
Why?
|
| Cholangiocarcinoma | 2 | 2023 | 493 | 0.770 |
Why?
|
| Malnutrition | 1 | 2023 | 218 | 0.760 |
Why?
|
| Hepatitis B, Chronic | 1 | 2022 | 137 | 0.750 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2020 | 44 | 0.730 |
Why?
|
| Liver Cirrhosis | 7 | 2023 | 941 | 0.410 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2195 | 0.350 |
Why?
|
| Fasting | 2 | 2020 | 349 | 0.320 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 551 | 0.320 |
Why?
|
| Antiviral Agents | 5 | 2023 | 1230 | 0.300 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 334 | 0.290 |
Why?
|
| Graft Survival | 2 | 2020 | 1062 | 0.280 |
Why?
|
| Risk Factors | 10 | 2023 | 17523 | 0.250 |
Why?
|
| Pancreatitis | 1 | 2007 | 267 | 0.250 |
Why?
|
| alpha-Fetoproteins | 2 | 2023 | 237 | 0.240 |
Why?
|
| Retrospective Studies | 14 | 2023 | 37905 | 0.240 |
Why?
|
| Humans | 34 | 2023 | 261506 | 0.230 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2023 | 27 | 0.230 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 77 | 0.220 |
Why?
|
| Hepatitis B e Antigens | 1 | 2022 | 10 | 0.220 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2023 | 85 | 0.220 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2022 | 27 | 0.210 |
Why?
|
| Hemochromatosis | 1 | 2022 | 35 | 0.210 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2023 | 59 | 0.210 |
Why?
|
| Hypertension, Portal | 1 | 2023 | 124 | 0.210 |
Why?
|
| Angiopoietin-2 | 1 | 2022 | 38 | 0.210 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 84 | 0.210 |
Why?
|
| Dietary Exposure | 1 | 2021 | 3 | 0.210 |
Why?
|
| Nitroso Compounds | 1 | 2021 | 17 | 0.210 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2021 | 21 | 0.200 |
Why?
|
| Diet, Western | 1 | 2021 | 23 | 0.200 |
Why?
|
| Diet Surveys | 1 | 2021 | 117 | 0.200 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2021 | 56 | 0.190 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 83 | 0.190 |
Why?
|
| Hepatitis | 1 | 2021 | 93 | 0.190 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2022 | 173 | 0.190 |
Why?
|
| Hepatitis B virus | 1 | 2022 | 217 | 0.180 |
Why?
|
| Dietary Fats | 1 | 2021 | 339 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2022 | 694 | 0.180 |
Why?
|
| Cause of Death | 1 | 2022 | 752 | 0.180 |
Why?
|
| Steroids | 1 | 2021 | 356 | 0.170 |
Why?
|
| Circadian Clocks | 1 | 2020 | 66 | 0.170 |
Why?
|
| Vegetables | 1 | 2021 | 325 | 0.170 |
Why?
|
| Hepatitis B | 1 | 2021 | 258 | 0.170 |
Why?
|
| Radiography | 1 | 2023 | 1904 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 551 | 0.160 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2019 | 181 | 0.160 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 421 | 0.160 |
Why?
|
| United States | 7 | 2022 | 15433 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 353 | 0.150 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 105 | 0.140 |
Why?
|
| Proteome | 1 | 2020 | 561 | 0.140 |
Why?
|
| Liver | 2 | 2017 | 2961 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2023 | 32848 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2020 | 769 | 0.130 |
Why?
|
| Time Factors | 4 | 2021 | 12926 | 0.130 |
Why?
|
| Adult | 11 | 2023 | 77950 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2023 | 6100 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 10035 | 0.120 |
Why?
|
| Prognosis | 5 | 2023 | 21713 | 0.120 |
Why?
|
| Kidney | 2 | 2017 | 2146 | 0.120 |
Why?
|
| Metabolomics | 1 | 2017 | 478 | 0.120 |
Why?
|
| Aged | 9 | 2022 | 70117 | 0.120 |
Why?
|
| Diet | 1 | 2021 | 1440 | 0.110 |
Why?
|
| Male | 13 | 2023 | 123000 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 1823 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 4320 | 0.100 |
Why?
|
| Sustained Virologic Response | 2 | 2023 | 57 | 0.100 |
Why?
|
| Obesity | 2 | 2023 | 2884 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 630 | 0.100 |
Why?
|
| Hepacivirus | 2 | 2023 | 397 | 0.090 |
Why?
|
| Middle Aged | 14 | 2023 | 86204 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2023 | 6869 | 0.090 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2008 | 24 | 0.080 |
Why?
|
| Female | 12 | 2021 | 141928 | 0.080 |
Why?
|
| Fascioliasis | 1 | 2007 | 6 | 0.080 |
Why?
|
| Fasciola hepatica | 1 | 2007 | 6 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2022 | 12873 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 4988 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2008 | 202 | 0.070 |
Why?
|
| Rectal Diseases | 1 | 2006 | 55 | 0.070 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2007 | 115 | 0.070 |
Why?
|
| Catheterization | 1 | 2008 | 410 | 0.070 |
Why?
|
| Drainage | 1 | 2008 | 416 | 0.070 |
Why?
|
| Pancreas | 1 | 2007 | 718 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 10331 | 0.060 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 613 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 30 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 2422 | 0.050 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 20 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2021 | 94 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2023 | 340 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2021 | 263 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 187 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 106 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 548 | 0.040 |
Why?
|
| Incidence | 2 | 2021 | 5673 | 0.040 |
Why?
|
| Child | 1 | 2020 | 29154 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 237 | 0.040 |
Why?
|
| North America | 1 | 2019 | 314 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2021 | 9244 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2020 | 267 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 159 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 368 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 498 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 279 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 429 | 0.040 |
Why?
|
| Life Style | 1 | 2021 | 612 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 483 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2021 | 2316 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2022 | 2218 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 602 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2020 | 1129 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 3441 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 2803 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 1248 | 0.030 |
Why?
|
| Cognition | 1 | 2020 | 968 | 0.030 |
Why?
|
| Proteomics | 1 | 2020 | 1380 | 0.030 |
Why?
|
| DNA Repair | 1 | 2020 | 1872 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Inflammation | 1 | 2020 | 2522 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2008 | 64 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13310 | 0.020 |
Why?
|
| Choristoma | 1 | 2006 | 85 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 9180 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 500 | 0.020 |
Why?
|
| Endosonography | 1 | 2008 | 536 | 0.020 |
Why?
|
| Equipment Design | 1 | 2008 | 1204 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 31252 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6207 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6009 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2006 | 375 | 0.010 |
Why?
|
| Animals | 2 | 2020 | 59536 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 34495 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 14889 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 7551 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 7702 | 0.010 |
Why?
|